KR101119845B1 - 동통 치료용 ＩκＢ 키나제 억제제의 용도 - Google Patents

동통 치료용 ＩκＢ 키나제 억제제의 용도 Download PDF

Info

Publication number
KR101119845B1
KR101119845B1 KR1020057002712A KR20057002712A KR101119845B1 KR 101119845 B1 KR101119845 B1 KR 101119845B1 KR 1020057002712 A KR1020057002712 A KR 1020057002712A KR 20057002712 A KR20057002712 A KR 20057002712A KR 101119845 B1 KR101119845 B1 KR 101119845B1
Authority
KR
South Korea
Prior art keywords
pain
alkyl
formula
atom
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057002712A
Other languages
English (en)
Korean (ko)
Other versions
KR20050058339A (ko
Inventor
마르틴 미카엘리스
올라프 리첼러
게르하르트 예네
카를 루돌피
게르트 가이쓰링어
한스-게오르그 샤이블레
Original Assignee
사노피-아벤티스 도이칠란트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피-아벤티스 도이칠란트 게엠베하 filed Critical 사노피-아벤티스 도이칠란트 게엠베하
Publication of KR20050058339A publication Critical patent/KR20050058339A/ko
Application granted granted Critical
Publication of KR101119845B1 publication Critical patent/KR101119845B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020057002712A 2002-08-17 2003-08-05 동통 치료용 ＩκＢ 키나제 억제제의 용도 Expired - Fee Related KR101119845B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10237723.5 2002-08-17
DE10237723A DE10237723A1 (de) 2002-08-17 2002-08-17 Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
PCT/EP2003/008628 WO2004022057A1 (de) 2002-08-17 2003-08-05 VERWENDUNG VON IκB-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020117028345A Division KR20110135428A (ko) 2002-08-17 2003-08-05 동통 치료용 ＩκＢ 키나제 억제제의 용도

Publications (2)

Publication Number Publication Date
KR20050058339A KR20050058339A (ko) 2005-06-16
KR101119845B1 true KR101119845B1 (ko) 2012-02-28

Family

ID=31968975

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020057002712A Expired - Fee Related KR101119845B1 (ko) 2002-08-17 2003-08-05 동통 치료용 ＩκＢ 키나제 억제제의 용도
KR1020117028345A Withdrawn KR20110135428A (ko) 2002-08-17 2003-08-05 동통 치료용 ＩκＢ 키나제 억제제의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117028345A Withdrawn KR20110135428A (ko) 2002-08-17 2003-08-05 동통 치료용 ＩκＢ 키나제 억제제의 용도

Country Status (33)

Country Link
EP (1) EP1531819B1 (https=)
JP (1) JP4504811B2 (https=)
KR (2) KR101119845B1 (https=)
CN (1) CN100398107C (https=)
AR (1) AR043045A1 (https=)
AT (1) ATE418336T1 (https=)
AU (1) AU2003271555B2 (https=)
BR (1) BR0313555A (https=)
CA (1) CA2495455C (https=)
CO (1) CO5690585A2 (https=)
CR (1) CR7716A (https=)
CY (1) CY1108874T1 (https=)
DE (2) DE10237723A1 (https=)
DK (1) DK1531819T3 (https=)
EC (1) ECSP055609A (https=)
ES (1) ES2320118T3 (https=)
HR (1) HRP20050041B1 (https=)
IL (1) IL166780A (https=)
MA (1) MA27334A1 (https=)
MX (1) MXPA05001218A (https=)
MY (1) MY138059A (https=)
NO (1) NO334309B1 (https=)
OA (1) OA12907A (https=)
PL (1) PL212356B1 (https=)
PT (1) PT1531819E (https=)
RS (1) RS51878B (https=)
RU (1) RU2320338C2 (https=)
SI (1) SI1531819T1 (https=)
TN (1) TNSN05044A1 (https=)
TW (1) TWI325782B (https=)
UA (1) UA80837C2 (https=)
WO (1) WO2004022057A1 (https=)
ZA (1) ZA200500323B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
EP1603450A4 (en) 2003-03-07 2009-07-29 Univ Columbia PROCEDURE BASED ON TYPE 1 RYANODIN RECEPTOR
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
DE102005025225A1 (de) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201242962A (en) 2010-12-01 2012-11-01 Sumitomo Chemical Co Pyrimidine compound and use for pest control thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
LT2787998T (lt) 2011-12-06 2017-02-10 Sanofi 2-(2-metilamino-pirimidin-4-il)-1h-indol-5-karboksirūgšties [(s)-1-karbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amido kristalinės formos
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
KR20170021884A (ko) * 2014-07-03 2017-02-28 사노피 골관절염에 연관된 통증의 치료에 사용하기 위한 2-(2-메틸아미노-피리미딘-4-일)-1h-인돌-5-카르복실산 [(s)-1-카르바모일-2-(페닐-피리미딘-2-일-아미노)-에틸]-아미드
CA3106124A1 (en) 2018-07-16 2020-01-23 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030774A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Deutschland Gmbh Substituierte indole zur modulierung von nfkb-aktivität

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1194425T1 (sl) * 1999-06-23 2005-12-31 Sanofi Aventis Deutschland Substituirani benzimidazoli
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030774A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Deutschland Gmbh Substituierte indole zur modulierung von nfkb-aktivität

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Molecular Interventions, Volume 2, Issue 1, 2002년 2월, pp.22-35*

Also Published As

Publication number Publication date
CN100398107C (zh) 2008-07-02
ECSP055609A (es) 2005-04-18
IL166780A0 (en) 2006-01-15
TWI325782B (en) 2010-06-11
OA12907A (en) 2006-10-13
CA2495455C (en) 2011-01-11
SI1531819T1 (sl) 2009-06-30
RS51878B (sr) 2012-02-29
KR20050058339A (ko) 2005-06-16
IL166780A (en) 2011-11-30
HRP20050041A2 (hr) 2006-04-30
JP2005539053A (ja) 2005-12-22
CR7716A (es) 2008-11-25
TW200417370A (en) 2004-09-16
EP1531819A1 (de) 2005-05-25
MXPA05001218A (es) 2005-05-16
WO2004022057A1 (de) 2004-03-18
HRP20050041B1 (hr) 2013-07-31
MY138059A (en) 2009-04-30
HK1079426A1 (en) 2006-04-07
KR20110135428A (ko) 2011-12-16
RU2005107419A (ru) 2005-08-10
DE10237723A1 (de) 2004-07-08
PT1531819E (pt) 2009-02-18
UA80837C2 (uk) 2007-11-12
PL373568A1 (en) 2005-09-05
EP1531819B1 (de) 2008-12-24
MA27334A1 (fr) 2005-05-02
CY1108874T1 (el) 2014-07-02
PL212356B1 (pl) 2012-09-28
BR0313555A (pt) 2005-07-12
CN1674899A (zh) 2005-09-28
DK1531819T3 (da) 2009-04-20
CO5690585A2 (es) 2006-10-31
ES2320118T3 (es) 2009-05-19
RU2320338C2 (ru) 2008-03-27
NO334309B1 (no) 2014-02-03
ATE418336T1 (de) 2009-01-15
RS20050070A (sr) 2007-06-04
NO20051339L (no) 2005-05-03
AR043045A1 (es) 2005-07-13
ZA200500323B (en) 2006-02-22
AU2003271555A1 (en) 2004-03-29
CA2495455A1 (en) 2004-03-18
JP4504811B2 (ja) 2010-07-14
TNSN05044A1 (en) 2007-05-14
AU2003271555B2 (en) 2009-03-26
DE50310980D1 (de) 2009-02-05

Similar Documents

Publication Publication Date Title
KR101119845B1 (ko) 동통 치료용 ＩκＢ 키나제 억제제의 용도
US8809358B2 (en) Use of IκB-kinase inhibitors in pain therapy
EP1261601B1 (de) Substituierte indole zur modulierung von nfkb-aktivität
KR20020012291A (ko) 치환된 벤즈이미다졸
HK1079426B (en) USE OF IκB KINASE INHIBITORS FOR THE TREATMENT OF PAIN
NZ538297A (en) Use of IkB kinase inhibitors for the treatment of pain
RU2415134C9 (ru) Способ лечения или профилактики физиологических и/или патофизиологических состояний, опосредуемых рецепторами, стимулирующими секрецию гормона роста, триазолы и фармацевтическая композиция на их основе
CN119451944A (zh) Prep结合配体

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A17-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20150119

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160218

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160218

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000